Abstract
Alzheimer's disease (AD) is a neurodegenerative disease mainly characterized by cognitive impairment and memory loss, which pathomechanism is unclear and hard for intervention and treatment at the early stage of the disease. The biomarkers presented by MR neuroimaging as objectively measurable parameters provide important evidence for early monitoring and diagnosis of AD. This paper reviews recent advances in biomarkers revealed by magnetic resonance imaging (MRI) in AD. The literature suggests that structural MRI can provide several biomarkers associated with memory loss in AD. The most mature MRI findings are hippocampal atrophy, which is associated with memory loss, and are now used as diagnostic criteria for AD. Neither task state functional MRI nor resting state functional MRI alone can provide biomarkers for AD. Multi-mode biomarker research using β-amyloid protein, positron emission computed tomography, structural MRI and functional MRI will be an important research direction in the future.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
